Samsung Biologics announced it has completed the acquisition of a manufacturing facility in Rockville, Maryland from GSK, marking a significant step in establishing its first manufacturing presence in the United States and expanding its global footprint.
The Rockville site includes two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters. The site supports both clinical and commercial biologics production across multiple scales.
The company said it will continue supplying products previously manufactured at the facility to GSK under the agreement, while transitioning the site to serve broader contract manufacturing needs. Samsung Biologics also plans to invest further to expand capacity and upgrade technologies at the location, strengthening long-term operations and supporting a more resilient global supply chain.
More than 500 employees at the Rockville site will join Samsung Biologics as part of the acquisition, bringing operational expertise to the company’s growing global manufacturing network.
The deal follows an earlier agreement announced on December 22, 2025, and represents a strategic move to diversify manufacturing geographically and enhance regional client support, particularly in the U.S. and Europe.
Samsung Biologics, a leading contract development and manufacturing organization, provides end-to-end services ranging from late-stage discovery to commercial manufacturing. The company continues to invest in new capabilities and infrastructure, including future expansion plans tied to its Bio Campus developments, to support next-generation therapies such as multispecific antibodies, antibody-drug conjugates, and mRNA therapeutics.
KEY QUOTE:
“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family. The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”
John Rim, President And CEO, Samsung Biologics
